Reimbursement Past Sema denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for reimbursement past sema are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Applies Quantity Limits to Semaglutide

Aetna's pharmacy benefit typically caps the quantity of semaglutide dispensed per fill or per authorization period. These limits are set in Aetna's formulary management system and are designed to align dispensing with the dosing schedule in the FDA-approved prescribing information. A quantity-limit denial fires automatically when the submitted quantity exceeds what the system allows — it does not reflect a clinical judgment about your specific patient.

## Why This Denial Is Appealable

Quantity-limit denials are among the most successfully appealed denial types. If your prescriber has documented a clinical reason for the quantity prescribed — for example, a titration schedule, a documented need to minimize refill gaps, or a supply situation — that medical justification can override the automatic limit. Aetna is required to have an exception process, and a well-documented medical-necessity argument routinely succeeds.

## Federal Appeal Framework

• Internal appeal: Under ACA §2719 and ERISA §503, you are entitled to a full-and-fair review of any adverse benefit determination, including quantity limits. Submit within the deadline in your denial letter.
• External review: If internal appeal is denied, escalate to an independent external reviewer within approximately four months. The reviewer evaluates whether the limit was clinically appropriate as applied to your patient.
• Expedited review: If a supply gap would cause urgent harm, request expedited review at the same time as the standard appeal.

## Documentation to Gather

1. Prescriber letter explaining the quantity — the prescribing clinician should state why the prescribed quantity is medically necessary for this patient, referencing the FDA-approved dosing range (from the label) and the specific titration or maintenance schedule being followed. 2. Current FDA prescribing information — attach the dosing section of the label to show the prescribed quantity falls within the approved range. 3. Clinical notes supporting the prescribed schedule — office visit notes documenting the treatment plan, response to date, and rationale for the current dosing interval. 4. Aetna's published quantity-limit criteria — obtain from Aetna's formulary or provider portal, and confirm whether a standard exception pathway exists and what it requires.

## Criteria-Mapping Structure

Frame the appeal as a structured exception request:

| Aetna Quantity-Limit Rule (copy verbatim from policy) | Patient-Specific Justification | |---|---| | Approved quantity per period | Prescribed quantity + prescriber rationale | | Dosing schedule basis (FDA label) | Specific titration / maintenance plan documented in chart | | Any exception criteria listed in policy | Corresponding clinical evidence |

Attach the denial letter, the prescriber letter, and the relevant FDA label dosing section as a single organized packet. Quantity-limit appeals are largely won or lost on the clarity and completeness of the prescriber's clinical explanation.